

## Doncaster & Bassetlaw Medicines Formulary

### Section 3.3 Leukotriene receptor antagonists and Phosphodiesterase type-4 inhibitors

**Montelukast 5mg tablets**

**Montelukast 4mg tablets**

**Montelukast 4mg granules**

**Montelukast 10mg tablets**

**Roflumilast 500mcg tablets**

Approved by Drug and Therapeutics Committee: March 2021

Review Date: March 2024

Prescribing Guidance:

Recommended as an alternative preventer therapy at step 3 and 4 of the BTS guidelines for management of asthma in adults:

[BTS guidelines for the Management of Asthma](#)

Use of leukotrienes does not necessarily result in a reduction in existing corticosteroid treatment.

Roflumilast is available for the management of COPD, where considered clinically appropriate in accordance with [NICE guidance](#). Roflumilast should only be initiated by a consultant respiratory physician and the side effects of the medication should be considered closely for each individual patient when assessing suitability of the product.